EMA reviewing GSK’s monoclonal antibodies to treat Covid-19
Early data shows an 85% reduction in risk of hospitalisaton and death, with similar treatment types already used against some cancers
15 April 2021 - 16:37
Bengaluru — The European Medicines Agency (EMA) said on Thursday that it is reviewing available data on the use of GlaxoSmithKline’s (GSK) monoclonal antibody to treat Covid-19 patients.
The agency said its review of VIR-7831, which GSK is developing with Vir Biotechnology, will include data from a study comparing its effect with that of a placebo in patients with mild to moderate Covid-19 who were at high risk of progressing to a more severe condition. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.